Trial Profile
Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2023
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Ramucirumab (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms RamAtezo-1
- 01 Nov 2022 Results published in the Lung Cancer.
- 10 Aug 2022 Planned End Date changed from 2 Nov 2023 to 25 Apr 2024.
- 09 Aug 2022 Primary endpoint overall response rate has not been met according to results presented at the 2022 World Conference on Lung Cancer